PL3074414T3 - Witanolidy przydatne do leczenia chorób neurodegeneracyjnych - Google Patents

Witanolidy przydatne do leczenia chorób neurodegeneracyjnych

Info

Publication number
PL3074414T3
PL3074414T3 PL14812105T PL14812105T PL3074414T3 PL 3074414 T3 PL3074414 T3 PL 3074414T3 PL 14812105 T PL14812105 T PL 14812105T PL 14812105 T PL14812105 T PL 14812105T PL 3074414 T3 PL3074414 T3 PL 3074414T3
Authority
PL
Poland
Prior art keywords
withanolides
useful
treatment
neurodegenerative diseases
neurodegenerative
Prior art date
Application number
PL14812105T
Other languages
English (en)
Polish (pl)
Inventor
Anthony A. Shaw
Jean-Pierre Julien
Agnes H. Chan
Original Assignee
Imstar Therapeutics Inc.
UNIVERSITé LAVAL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imstar Therapeutics Inc., UNIVERSITé LAVAL filed Critical Imstar Therapeutics Inc.
Publication of PL3074414T3 publication Critical patent/PL3074414T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J71/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005Oxygen-containing hetero ring
    • C07J71/001Oxiranes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL14812105T 2013-11-25 2014-11-25 Witanolidy przydatne do leczenia chorób neurodegeneracyjnych PL3074414T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361908455P 2013-11-25 2013-11-25
PCT/US2014/067436 WO2015077780A1 (en) 2013-11-25 2014-11-25 Withanolides useful for the treatment of neurodegenerative diseases
EP14812105.6A EP3074414B1 (en) 2013-11-25 2014-11-25 Withanolides useful for the treatment of neurodegenerative diseases

Publications (1)

Publication Number Publication Date
PL3074414T3 true PL3074414T3 (pl) 2019-12-31

Family

ID=52023694

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14812105T PL3074414T3 (pl) 2013-11-25 2014-11-25 Witanolidy przydatne do leczenia chorób neurodegeneracyjnych

Country Status (14)

Country Link
US (1) US10351590B2 (enExample)
EP (1) EP3074414B1 (enExample)
JP (1) JP6517833B2 (enExample)
KR (1) KR20160137945A (enExample)
CN (1) CN105940010B (enExample)
AU (1) AU2014352629B2 (enExample)
BR (1) BR112016012002A2 (enExample)
CA (1) CA2931064C (enExample)
ES (1) ES2728870T3 (enExample)
MX (1) MX364528B (enExample)
PL (1) PL3074414T3 (enExample)
TR (1) TR201905218T4 (enExample)
WO (1) WO2015077780A1 (enExample)
ZA (1) ZA201603117B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210087222A1 (en) * 2017-12-11 2021-03-25 Ethnodyne Compounds for treating neurodegenerative disorders
EP3724170B1 (en) 2017-12-11 2022-04-27 Ethnodyne Compounds for treating neurodegenerative disorders
EP3724207A1 (en) * 2017-12-11 2020-10-21 Ethnodyne Compounds for treating neurodegenerative disorders
CN111377994A (zh) * 2018-12-28 2020-07-07 南开大学 七种来源于灯笼果的醉茄内酯类化合物及其制备方法和用途
CN116063373B (zh) * 2023-02-14 2025-04-15 广西医科大学 天然产物27-Deoxywithaferin A的制备方法
TW202521103A (zh) * 2023-10-03 2025-06-01 美商恩維達醫療公司 醉茄素a(withaferin a)類似物及使用彼之治療方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010030395A2 (en) 2008-09-15 2010-03-18 Whitehead Institute For Biomedical Research Withaferin a analogs and uses thereof
WO2010053655A2 (en) * 2008-11-07 2010-05-14 University Of Kansas Therapeutic methods with withaferin a and analogs
WO2012106393A2 (en) * 2011-02-01 2012-08-09 University Of Kansas Withanolide isolated from physalis longifolia and analogs and methods of use thereof
EP2723866B1 (en) 2011-06-22 2018-03-28 Universite Laval Methods for the prognostic and/or diagnostic of neurodegenerative disease, methods to identify candidate compounds and compounds for treating neurodegenerative disease

Also Published As

Publication number Publication date
ES2728870T3 (es) 2019-10-29
JP2016537432A (ja) 2016-12-01
BR112016012002A2 (pt) 2017-09-19
CN105940010A (zh) 2016-09-14
AU2014352629A1 (en) 2016-05-26
CA2931064A1 (en) 2015-05-28
CA2931064C (en) 2022-10-18
MX364528B (es) 2019-04-30
EP3074414B1 (en) 2019-01-09
MX2016006544A (es) 2016-12-12
WO2015077780A1 (en) 2015-05-28
CN105940010B (zh) 2018-03-30
US10351590B2 (en) 2019-07-16
ZA201603117B (en) 2020-05-27
EP3074414A1 (en) 2016-10-05
AU2014352629B2 (en) 2019-03-28
JP6517833B2 (ja) 2019-05-22
US20170022247A1 (en) 2017-01-26
KR20160137945A (ko) 2016-12-02
TR201905218T4 (tr) 2019-05-21

Similar Documents

Publication Publication Date Title
IL273815B (en) Secondary vaccine particles for the treatment of inflammation
IL287516A (en) Medicinal uses of empagliflozin
IL243976A0 (en) kdm1a inhibitors for disease treatment
IL239368A0 (en) Sparing–ppar thiazolidinediones and combinations for the treatment of neurodegenerative diseases of the nervous system
IL241264A0 (en) Compounds and compositions for the treatment of parasitic diseases
IL241101B (en) Medicinal uses of empagliflozin
IL244014A0 (en) Combined therapy for the treatment of glioblastoma
IL241102B (en) Medicinal uses of empagliflozin
SG11201509012QA (en) Sobetirome in the treatment of myelination diseases
SI2981271T1 (sl) Terapevtske uporabe empagliflozina
EP2906583A4 (en) PEPTIDES FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
PL3062790T3 (pl) Połączenia farmaceutyczne do leczenia raka
ZA201603117B (en) Withanolides useful for the treatment of neurodegenerative diseases
EP3013824B8 (en) Carboline compounds usable in the treatment of neurodegenerative diseases
ZA201507718B (en) The local treatment of inflammatory ophthalmic diseases
IL243637B (en) PPAR-sparing compounds for the treatment of metabolic diseases
EP3089984A4 (en) NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES
IL234796B (en) Compounds for the treatment of diseases related to ischemia-reperfusion
HK40097140A (zh) 治疗线粒体疾病的方法
PL3016948T3 (pl) 2-acyloaminotiazole do leczenia nowotworów
HK40032828A (en) Methods for the treatment of mitochondrial disease
HK40009827B (en) Immune-modifying particles for the treatment of inflammation
GB201306413D0 (en) The local treatment of ophthalmic diseases
GB201321628D0 (en) Treatment of disease
AU2013904239A0 (en) Pharmaceutical combinations for the treatment of cancer